Brief: Gossamer Bio Q3 EPS USD -0.14
07/11/2024 21:03
Nov 07 (Reuters) - Gossamer Bio Q3 operating expenses USD 43.399 million. * Q3 basic EPS USD -0.14 * Q3 net income USD -30.803 million * Q3 operating income USD -33.919 million
Recent news on Gossamer Bio
See all newsBrief: Gossamer Bio Submits New Drug Application To US FDA For Seralutinib For The Treatment Of Pulmonary Arterial Hypertension
NASDAQ RESUMED AT 09:00 AM
NASDAQ TRADE HALT CONTINUES REASON NOT AVAILABLE AT 03:58 AM
NASDAQ TRADE HALT HALT NEWS PENDING AT 07:50 PM
Brief: Gossamer Bio - Board Approves Amendment And Restatement Of Bylaws Effective Sept 3, 2026 - SEC Filing